Adenosine and uridine 5′-tetra-and 5′pentaphosphates were synthesized from an activated tetrametaphosphate ([PPN] 2 [P 4 O 11 ], [PPN] 2 [1], PPN = bis(triphenylphosphine)iminium) and subsequently tested for inhibition of the enzymatic activity of ribonuclease A (RNase A). Reagent [PPN] 2 [1] reacts with unprotected uridine and adenosine in the presence of a base under anhydrous conditions to give nucleoside tetrametaphosphates. Ring opening of these intermediates with tetrabutylammonium hydroxide ([TBA][OH]) yields adenosine and uridine tetraphosphates (p 4 A, p 4 U) in 92% and 85% yields, respectively, from the starting nucleoside. Treatment of ([PPN] 2 [1]) with AMP or UMP yields nucleoside-monophosphate tetrametaphosphates (cp 4 pA, cp 4 pU) having limited aqueous stability. Ring opening of these ultraphosphates with [TBA]
S ecretory ribonucleases (RNases) are a diverse family of enzymes that catalyze the cleavage of RNA to elicit biological functions ranging from cell signaling to innate immunity. 1, 2 Fundamental knowledge generated by studying RNase A, which derives from the bovine pancreas, has shaped the fields of enzymology and protein chemistry. 3, 4 Furthermore, mammalian RNases have been shown to have angiogenic 5 and neurotoxic activities, 6 and targeted inhibitors of these enzymes may have human therapeutic potential. 7 RNase A binds its substrates in enzymic subsites that interact with phosphoryl groups and nucleobases ( Figure 1 ). 8, 9 Atypical nucleotides are among the best small-molecule inhibitors of RNase A. Diadenosine oligophosphates ( Table 1 , entries 5−7) are micromolar to submicromolar inhibitors that exhibit increasing affinity with longer phosphate chain lengths. 10 Additionally, the highest affinity small-molecule inhibitors of RNase A, pyrophosphate-linked dinucleotides ( Table 1 , entries 1−4), have enhanced inhibition activity upon further phosphorylation. 11 These observations prompted us to ask: can a simple oligophosphate on its own or appended to a single nucleoside serve as an effective small-molecule inhibitor of RNase A? Figure 1 . Cocrystal structure of RNase A bound to an AUAA DNA tetramer revealed the subsites that recognize nucleobases and phosphoryl groups (1rcn, top). The mainchain of RNase A is traced with a cartoon, key active-site and cysteine residues are shown as sticks, and ligands are shown as balls-and-sticks. Residues in subsites are colored blue (P 2 ), red (P 1 ), and green (P 0 ). A cartoon representation of the RNase A active site showing the preferred binder for each subsite (bottom). For simplicity, the P −1 subsite 12 is not shown.
In addition to canonical nucleoside mono-, di-, and triphosphates, nucleosides bearing longer oligophosphate chains are potent signaling molecules in biology. 14−18 These and other related morphologies, such as dinucleotide oligophosphates, 19−21 have been implicated in a variety of biological processes and ailments including hypertension 22 and bacterial accumulation of polyphosphate. 23−26 Nonetheless, the synthesis of oligophosphorylated compounds typically increases in difficulty with longer phosphate chains. Recently, methods have been developed to efficiently couple a triphosphate chain in one operation from trimetaphosphate (P 3 O 9 3− ). 14,27−32 Here, we extend this methodology to the tetraphosphorylation of biomolecules, utilizing tetrametaphosphate (P 4 O 12 4− ) to synthesize nucleoside tetraphosphates (p 4 N) and nucleoside pentaphosphates (p 5 N). Previous syntheses of p 4 N have suffered from extremely low yields, 33 requiring nucleoside triphosphates as starting materials, 34 or iterative syntheses to add each additional phosphoryl group. 13, 23 The state-of-the-art synthesis of p 4 N involves coupling of trimetaphosphate and nucleoside monophosphates. 14 Here, we describe the facile synthesis of p 4 N and p 5 N by coupling tetrametaphosphate with nucleosides and nucleoside monophosphates, respectively ( Figure 2 ). Utilizing tetraphosphorylation reagent 1 permits unprotected nucleosides to be converted to the corresponding p 4 N efficiently in a single operation. This is in contrast to the method of Taylor, which requires nucleoside monophosphates as the substrate. 14 While enzymatic methods have been reported, 35−37 the few reported chemical syntheses of p 5 N have been limited in scope and low yielding. 23, 33 The activated tetrametaphosphate, [PPN] 2 [1] , is synthesized by protonation of tetrametaphosphate and subsequent dehydration. 38 Treatment of adenosine or uridine with [PPN] 2 [1] under rigorously anhydrous conditions leads to selective phosphorylation of the 5′ position. No satisfactory purification could be found for the resulting nucleosidesubstituted tetrametaphosphates (cp 4 N, Figure 3 ), but treatment with [ (Figure 3 ).
Reagent 1 is highly moisture sensitive and must be prepared, stored, and utilized in an anhydrous environment, ideally inside a glovebox. We therefore developed a second phosphorylation methodology for the syntheses of both p 4 N and p 5 N, activating [PPN] 2 [P 4 O 12 H 2 ] 38 in situ with dicyclohexylcarbodiimide (DCC) to form reagent 1. These reagents are bench stable, and this methodology can be utilized 
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Communication conveniently with a Schlenk line, although it suffers from lower yields (SI Sections 2.2 and 2.5).
We performed inhibition kinetics using a fluorogenic substrate as described previously 39 to assess the binding of oligophosphates to RNase A. In addition to the synthesized molecules, p 4 N and p 5 N, we assessed inhibition kinetics for a variety of inorganic phosphates to evaluate our hypothesis that longer oligophosphate chains increase binding affinity. Complementing previous reports of weak RNase A inhibition by orthophosphate (P i , Table 1 , entry 8) and pyrophosphate (P 2i , Table 1 , entry 9), we tested P 3i and P 4i (Table 1, entries 10−11). The measured K i values decrease for longer phosphates with a value of 23 μM for P 4i . Although a longer inorganic oligophosphate may be a more potent inhibitor, each subsequent phosphoryl group has a diminished impact on lowering the K i value. We similarly tested inorganic tri-(cP 3i , Table 1 , entry 12), tetra-(cP 4i , Table 1 , entry 13), and hexametaphosphate (cP 6i , Table 1 , entry 14) as these cyclic phosphates have been largely ignored in biological systems despite their indefinite stabilities near neutral pH. A similar trend was observed with increased inhibition of RNase A for longer oligophosphates and diminishing returns for each additional phosphoryl group. The metaphosphates are modestly less effective inhibitors than the corresponding linear phosphate.
Inhibition of RNase A by adenosine nucleotides does not follow the same simple trend as inorganic phosphates. Reported K i values are given in Table 1 , entries 15−19 for adenosine 5′-oligophosphates ranging from monophosphate (pA) to pentaphosphate (p 5 A). Inhibition increases from pA to the strongest inhibitor of this series, p 3 A with a K i value of 0.86 μM. p 4 A and p 5 A are somewhat less effective inhibitors with K i values of 2.1 and 1.4 μM, respectively, indicating that the role of the oligophosphate chain in binding is not reducible simply to a Coulombic interaction. Furthermore, we tested the hydrolytically sensitive ultraphosphate cp 4 pA and found that it was a superior inhibitor with a K i value of 0.48 μM (Table 1 , entry 20), suggesting that this unusual phosphate geometry is better able to target the active site.
In contrast to 5′-adenosine nucleotides, RNase A inhibition by 5′-uridine nucleotides follows a simple trend analogous to inorganic phosphates. In the series pU to p 5 U ( Table 1 , entries 22−26), inhibition increases successively with longer oligophosphate chains, and the strongest inhibitor is p 5 U with a K i value of 0.068 μM. This mononucleotide approaches the potency of the best pyrophosphate-linked dinucleotide inhibitors of RNase A (Table 1, entries 2 and 4 ). 11 The ultraphosphate species cp 4 pU is, however, a weaker inhibitor with a K i value of 0.98 μM (Table 1, entry 27 ). Finally, we assessed the salt dependence of inhibition by p 5 U. Compared to a DNA tetramer AUAA, which exhibits a δlogK d /δlog[Na + ] of 2.3, 8 p 5 U has a greater value of 3.2 (Figure S30) , indicating a greater dependence on Coulombic interactions. Nonetheless, p 5 U is among the most potent small-molecule inhibitors reported of RNase A and maintains high affinity at physiological salt concentrations.
To understand the differing trends in inhibition of RNase A by adenosine and uridine nucleotides, we solved X-ray cocrystal structures of several of these ligands bound to RNase A. The structure of bound cP 6i , which is the first protein crystal structure to contain a metaphosphate, shows the ligand bound primarily in the P 1 subsite ( Figure S31A ). This is analogous to structures of bound P i (5rsa) 44 and P 2i (2w5m), 45 suggesting that the binding of these inorganic phosphates is largely conserved. Differences in inhibition are attributable to Coulombic interactions and slight variations in hydrogen bonding.
The enhanced inhibition of p 3 A over other adenosine nucleotides is illuminated by crystallography. In structures of both p 3 A (2w5g, Figure 4A) 45 and p 5 A (6pvv, Figure 4B ), the terminal phosphoryl group of the oligophosphate chain binds in the P 1 subsite with hydrogen bonds to His12 and His119. For the longer oligophosphate in p 5 A to target the same site requires the phosphate chain to form a loop. Apparently, the thermodynamic penalty associated with this constrained geometry is sufficient to overcome the greater Coulombic attraction between the enzyme and the more highly charged pentaphosphate, resulting in weaker inhibition. Furthermore, the strong inhibition by cp 4 pA is attributable in part to more efficient targeting of Lys7 in this unusual phosphate geometry (6pvw, Figure 4C ).
In 5′-uridine nucleotides, longer oligophosphate chains are not detrimental to inhibition of RNase A. Pyrimidine nucleobases are preferred in the B 1 subsite, but a previous structure of p 2 U revealed occupancy of both the P 0 /B 1 and P 1 /B 2 subsites by a pair of these ligands (3dxh, Figure 4D ). Chain A of the structure of p 5 U bound to RNase A (6pvx, Figure 4E ) shares this mode of recognition; however, only a single p 5 U binds the P 1 /B 1 subsites in chain B ( Figure 4F ). In both chains, the oligophosphates extend well beyond the phosphoryl group-binding subsites and can efficiently target several cationic regions of the active-site cleft. Thermodynamically unfavorable constraints are not imposed on the polyphosphate chain; therefore, longer, more highly charged oligophosphates could improve affinity of 5′-uridine nucleotides.
The role of polyphosphates in biological systems has come under increasing study. Here, we contribute to the synthetic methodology to create these species as well as perform analyses of their function. The activated tetrametaphosphate reagent [PPN] 2 [1] is a useful synthetic tool for synthesizing polyphosphate chains of four units or longer by reaction with suitable anhydrous nucleophiles. Furthermore, intermediates containing substituted metaphosphates can, in some cases, be isolated as pure compounds that possess modest aqueous stability. We showed that binding of polyphosphorylated compounds to the active-site cleft of RNase A generally follows the simple trend that affinity increases with oligophosphate length, with 5′-adenosine oligophosphates being the notable exception. The limit of affinity enhancement conferred by lengthening the phosphate chain of 5′-uridine nucleotides remains to be determined, and we are working toward synthesizing p 6 U as well as exploring phosphorylation on 3′nucleotide positions. Furthermore, this work presents the first crystal structures of a metaphosphate ( Figure S31A ) or an ultraphosphate ( Figure 4C ) bound to a protein. This demonstrates that complex polyphosphate morphologies that have been largely excluded from consideration in aqueous media may in fact be relevant to biological systems, opening new avenues for biochemical studies and drug development.
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